KMDA - Kamada logo

Kamada manufactures and sells plasma-derived protein therapeutics, including treatments for rabies, cytomegalovirus, asthma, and various immunodeficiencies. The company also distributes biopharmaceutical products in Israel for multiple medical conditions.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$1,784today

Score Overview

1 Year
Score
Net Growth0.83%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth0.68%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.2
Net Growth11x
Net Trend80%
Net Income Consistencyโ€”
Rev Growth75.30%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth402.48%
Net Trend60%
Net Income Consistency
Rev Growth134.45%
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth45x
Net Trend62%
Net Income Consistency
Rev Growth157.26%
Rev Trend85%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Kamada has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. KMDA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 8.46โ€”
1 Year2025-09-30
$ 6.6028.20%
5 Years2021-09-30
$ 4.9072.67%
10 Years2016-09-30
$ 4.7478.40%
All Time2013-05-31
$ 9.33-9.34%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 181M$ 20M$ 73M
2025$ 180M$ 20M$ 75M
2024$ 160M$ 14M$ 78M
2023$ 142M$ 8M$ 55M
2022$ 129M-$ 2M$ 34M
2021$ 103M-$ 2M$ 18M
2020$ 133M$ 17M$ 109M
2019$ 127M$ 22M$ 73M
2018$ 114M$ 22M$ 50M
2017$ 102M$ 6M$ 43M
2016$ 77M-$ 6M$ 28M
2015$ 70M-$ 11M$ 28M
2014$ 71M-$ 12M$ 51M
IPO2013$ 70M$ 443K$ 74M
KMDA - Kamada logo

Kamada fundamental performance

Between 2020 and 2025, revenue grew from $ 133M to $ 180M and net income grew from $ 17M to $ 20M. Revenue increased in every one of those 5 years; net income in 4.

Across Kamada's full reported history, from 2013 to 2025, revenue grew from $ 70M to $ 180M and net income grew from $ 443K to $ 20M. Revenue increased in 85% of the years measured; net income in 62%.

Kamada currently holds a 5-year HDB Score of 8.2 out of 10. How the HDB Score is calculated.

Membership

Explore KMDA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies